2026-06-28T16:25:31Z https://icatplus.esrf.fr/oaipmh/request

oai:icatplus.esrf.fr:inv/2099419816 2025-03-29T16:00:11.549Z

4.2 EI 10.15151/ESRF-ES-2099419816 Karolina SEDLACKOVA Karolina Sedlackova 0009-0009-4924-2493 Karolina SEDLACKOVA Karolina Sedlackova 0009-0009-4924-2493 David FLOT David Flot 0000-0001-6639-7205 Andrew MCCARTHY Andrew Mc Carthy 0000-0003-4478-0136 Martin MAREK Martin Marek 0000-0001-7220-5644 Martin MAREK Martin Marek 0000-0001-7220-5644 Example Institute 2028 Data from large facility measurement 2025-03-28T16:00:00Z/2025-03-29T16:00:00Z 2025-03-29T16:00:00Z I CC-BY-4.0 Within the proposed experiment, we aim to collect monochromatic and anomalous crystallographic data on ligand-free and ligand-bound protein targets. First, we will focus on staphylokinase (SAK), a pharmacologically attractive indirect plasminogen activator protein of bacterial origin that forms stoichiometric noncovalent complexes with plasmin, promoting the conversion of plasminogen into plasmin. We will probe biocrystals of a non-immunogenic SAK, which we recently prepared in our lab. Moreover, we will aim to collect crystallographic data on Apolipoprotein E4 (ApoE4) isoform, which is a key player in the neurodegenerative diseases. Specifically, we aim at dissecting the molecular mechanism of ApoE oligomerization, that leads to pathological aggregates frequently found in brains of AD patients. The gained structural knowledge will navigate drug discovery pipeline to identify small molecules specifically preventing ApoE aggregation. Finally, we will probe crystals of a newly discovered